Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche
NAARDEN, The Netherlands & BRIGHTON, England--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces that its portfolio...